Medacta Group SA
SIX:MOVE
Intrinsic Value
Medacta Group SA engages in the development, manufacture, and distribution of orthopedic and neurosurgical medical devices. [ Read More ]
The intrinsic value of one MOVE stock under the Base Case scenario is 127.14 CHF. Compared to the current market price of 111.4 CHF, Medacta Group SA is Undervalued by 12%.
Valuation Backtest
Medacta Group SA
Run backtest to discover the historical profit from buying and selling MOVE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Medacta Group SA
Current Assets | 348.5m |
Cash & Short-Term Investments | 27.8m |
Receivables | 106.7m |
Other Current Assets | 213.9m |
Non-Current Assets | 347.4m |
Long-Term Investments | 712k |
PP&E | 267.3m |
Intangibles | 51.4m |
Other Non-Current Assets | 27.9m |
Current Liabilities | 149.4m |
Accounts Payable | 38.9m |
Accrued Liabilities | 40.2m |
Other Current Liabilities | 70.4m |
Non-Current Liabilities | 216.4m |
Long-Term Debt | 148.2m |
Other Non-Current Liabilities | 68.2m |
Earnings Waterfall
Medacta Group SA
Revenue
|
510.8m
EUR
|
Cost of Revenue
|
-162.9m
EUR
|
Gross Profit
|
347.8m
EUR
|
Operating Expenses
|
-272.1m
EUR
|
Operating Income
|
75.7m
EUR
|
Other Expenses
|
-28.4m
EUR
|
Net Income
|
47.4m
EUR
|
Free Cash Flow Analysis
Medacta Group SA
MOVE Profitability Score
Profitability Due Diligence
Medacta Group SA's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Medacta Group SA's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
MOVE Solvency Score
Solvency Due Diligence
Medacta Group SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Medacta Group SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MOVE Price Targets Summary
Medacta Group SA
According to Wall Street analysts, the average 1-year price target for MOVE is 146.46 CHF with a low forecast of 131.3 CHF and a high forecast of 161.7 CHF.
Shareholder Return
MOVE Price
Medacta Group SA
Average Annual Return | 8.35% |
Standard Deviation of Annual Returns | 42.99% |
Max Drawdown | -53% |
Market Capitalization | 2.2B CHF |
Shares Outstanding | 19 957 500 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Medacta Group SA engages in the development, manufacture, and distribution of orthopedic and neurosurgical medical devices. The company is headquartered in Castel San Pietro, Ticino and currently employs 1,341 full-time employees. The company went IPO on 2019-04-04. The firm develops, manufactures and distributes orthopaedic and neurosurgical medical devices. The firm designs a number of products, such as hip products, including hip replacement, hip anatomy, hip diseases, and other products for the preparation of hip surgery; knee product, which encompasses knee anatomy, knee diseases, knee replacement, the stability of the knee and for the preparation of knee surgery; shoulder product, which includes shoulder anatomy, shoulder disease, shoulder replacement, and for the preparation of shoulder operation, and spine product, which includes products for spinal treatments, spinal anatomy and for surgery, among others. Additionally, the Company also offers training and support to healthcare professionals.
Contact
IPO
Employees
Officers
The intrinsic value of one MOVE stock under the Base Case scenario is 127.14 CHF.
Compared to the current market price of 111.4 CHF, Medacta Group SA is Undervalued by 12%.